Aarti Pharmalabs Ltd's Q4FY25 Quarter Results
- 1d ago
Result Summary
- Aarti Pharmalabs Ltd reported a 6.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 4.5%.
- Its expenses for the quarter were down by 6.8% QoQ and 3.5% YoY.
- The net profit decreased 11.8% QoQ and increased 52.2% YoY.
- The earnings per share (EPS) of Aarti Pharmalabs Ltd stood at 7.2 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 507.80 | 542.81 | 485.80 | -6.4% | 4.5% |
Total Expenses | 412.05 | 442.18 | 426.95 | -6.8% | -3.5% |
Profit Before Tax | 95.75 | 100.63 | 58.85 | -4.8% | 62.7% |
Tax | 30.50 | 26.64 | 15.98 | 14.5% | 90.9% |
Profit After Tax | 65.25 | 73.99 | 42.87 | -11.8% | 52.2% |
Earnings Per Share | 7.20 | 8.20 | 4.70 | -12.2% | 53.2% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Aarti Pharmalabs Ltd is a prominent entity in the pharmaceutical industry, primarily engaged in the production and supply of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialty chemicals. The company caters to a variety of therapeutic segments and is known for its robust research and development capabilities, which support its product innovation and market expansion strategies. Aarti Pharmalabs has consistently focused on enhancing its manufacturing processes to ensure high-quality deliverables to its clients. As of the latest update, detailed information regarding recent major developments or expansions within the company is not available. However, the company continues to operate in a competitive sector, which is characterized by stringent regulations and evolving market demands.
Revenue
In the fourth quarter of the fiscal year 2025 (Q4FY25), Aarti Pharmalabs Ltd reported total income of ₹507.80 crores. This represents a decrease of 6.4% from the previous quarter (Q3FY25), where total income stood at ₹542.81 crores. When compared to the same quarter in the previous year (Q4FY24), which recorded a total income of ₹485.80 crores, there is a year-over-year increase of 4.5%. This indicates a positive year-over-year growth despite the quarter-over-quarter decline. The revenue figures reflect the company's performance in the face of industry challenges and changing economic conditions.
Profitability
The company's profitability metrics for Q4FY25 showed a Profit Before Tax (PBT) of ₹95.75 crores, a slight decrease of 4.8% QoQ from ₹100.63 crores in Q3FY25. This PBT, however, marks a significant YoY increase of 62.7% compared to ₹58.85 crores in Q4FY24. After accounting for tax expenses, the Profit After Tax (PAT) for Q4FY25 was ₹65.25 crores, reflecting a decrease of 11.8% QoQ from ₹73.99 crores in Q3FY25. Nevertheless, the PAT YoY growth was substantial at 52.2% from ₹42.87 crores in Q4FY24. These figures highlight the company's ability to maintain a strong YoY growth trajectory in profitability despite the QoQ challenges.
Operating Metrics
During Q4FY25, Aarti Pharmalabs Ltd's total expenses were reported at ₹412.05 crores, which is a reduction of 6.8% from ₹442.18 crores in the previous quarter, Q3FY25. Compared to the same period in the previous year (Q4FY24), where total expenses were ₹426.95 crores, there was a YoY decrease of 3.5%. The Earnings Per Share (EPS) for Q4FY25 was ₹7.20, showing a decline of 12.2% QoQ from ₹8.20 in Q3FY25, but a YoY increase of 53.2% from ₹4.70 in Q4FY24. The tax expense for the quarter was ₹30.50 crores, which was 14.5% higher than the previous quarter's ₹26.64 crores and 90.9% higher than the ₹15.98 crores in Q4FY24. These operating metrics reflect the company's financial dynamics and its ability to manage expenses effectively while navigating through different fiscal challenges.
